Advanced Accelerator Applications Receives 2017 Industry Innovation Award from National Organization for Rare Disorders for NETSPOT®, a Diagnostic Drug for Neuroendocrine Tumors
May 18, 2017 07:00 ET
|
Advanced Accelerator Applications
SAINT-GENIS-POUILLY, France, May 18, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), an international specialist in Molecular Nuclear Medicine...
Advanced Accelerator Applications Signs Strategic Supply Agreement with University of Missouri for Lutetium 177
March 30, 2017 07:30 ET
|
Advanced Accelerator Applications
SAINT-GENIS-POUILLY, France, March 30, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (AAA or the Company), an international specialist in Molecular Nuclear Medicine...
Advanced Accelerator Applications Reports 23% Sales Growth for Fiscal 2016; Continued NETSPOT® Launch Success
March 23, 2017 07:30 ET
|
Advanced Accelerator Applications
On Track to Resubmit NDA for lutetium Lu 177 dotatate (Lutathera®) to FDA in Mid-2017 Conference Call Today at 10:00 a.m. ET 2016 Key Events: Sales for full-year 2016 increased 23% compared to...
Advanced Accelerator Applications to Announce Full-Year 2016 Financial Results on March 23
March 15, 2017 07:00 ET
|
Advanced Accelerator Applications
SAINT-GENIS-POUILLY, France, March 15, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or the “Company”), an international specialist in Molecular Nuclear...
Advanced Accelerator Applications Announces Presentation of Quality of Life Findings from NETTER-1 Phase III Study at ENETS
March 06, 2017 07:00 ET
|
Advanced Accelerator Applications
SAINT-GENIS-POUILLY, France, March 06, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or the “Company”), an international specialist in Molecular Nuclear...
Advanced Accelerator Applications Announces Addition of NETSPOT® to National Comprehensive Cancer Network® Guidelines for Evaluation of NETs
March 01, 2017 07:00 ET
|
Advanced Accelerator Applications
SAINT-GENIS-POUILLY, France, March 01, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or the “Company”), an international specialist in Molecular Nuclear...
Advanced Accelerator Applications Announces New England Journal of Medicine Publication of Lutathera® NETTER-1 Phase III Results
January 12, 2017 08:05 ET
|
Advanced Accelerator Applications
SAINT-GENIS-POUILLY, France, Jan. 12, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or “the Company”), an international specialist in Molecular Nuclear...
Advanced Accelerator Applications CEO Provides Progress Report on Corporate Developments of 2016; Asserts Confidence in Ability to Address FDA Comments on Lutathera® NDA
January 09, 2017 07:00 ET
|
Advanced Accelerator Applications
SAINT-GENIS-POUILLY, France, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or “the Company”), an international specialist in Molecular Nuclear...
Advanced Accelerator Applications to Present at 35th Annual J.P. Morgan Healthcare Conference
January 04, 2017 07:00 ET
|
Advanced Accelerator Applications
SAINT-GENIS-POUILLY, France, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or “the Company”), an international specialist in Molecular Nuclear...
Advanced Accelerator Applications Receives Complete Response Letter from FDA for Lutathera®, an Investigational Treatment for Neuroendocrine Tumors
December 21, 2016 07:00 ET
|
Advanced Accelerator Applications
SAINT-GENIS-POUILLY, France, Dec. 21, 2016 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or the “Company”), an international specialist in Molecular Nuclear...